-
公开(公告)号：US08987195B2
公开(公告)日：2015-03-24
申请号：US13960343
申请日：2013-08-06
Applicant: Merck Sharp & Dohme Corp. , Merck Canada Inc.
Inventor： Thomas Bara , Sathesh Bhat , Dipshikha Biswas , Linda Brockunier , Duane A. Burnett , Samuel Chackalamannil , Mariappan V. Chelliah , Austin Chen , Martin Clasby , Vince J. Colandrea , Zhuyan Guo , Yongxin Han , Charles Jayne , Hubert Josien , Karen Marcantonio , Shouwu Miao , Santhosh Neelamkavil , Patrick Pinto , Murali Rajagopalan , Unmesh Shah , Francisco Velazquez , Srikanth Venkatraman , Yan Xia
IPC: A61K38/00 , C07K5/08 , A61K38/06 , A61K45/06 , C07D491/22 , C07D419/00
CPC classification number: C07K5/08 , A61K38/06 , A61K45/06 , C07D419/00 , C07D491/22
Abstract: The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.
Abstract translation: 本发明涉及含有螺环状的丙型肝炎病毒（HCV）NS3蛋白酶抑制剂，这些化合物的用途，以及这些化合物的合成。
-
公开(公告)号：US09745295B2
公开(公告)日：2017-08-29
申请号：US14786464
申请日：2014-04-22
Applicant: Merck Sharp & Dohme Corp. , Merck Canada Inc.
Inventor： Neville J. Anthony , Brian M. Andresen , Alan B. Northrup , Kaleen K. Childers , Anthony Donofrio , Thomas A. Miller , Yuan Liu , Michelle R. Machacek , Hyun Chong Woo , Kerrie B. Spencer , John Michael Ellis , Michael D. Altman , Eric T. Romeo , Daniel Guay , Jonathan Grimm , Marie-Eve Lebrun , Joel S. Robichaud , Liping Wang , Byron DuBois , Qiaolin Deng
IPC: A61K31/4439 , A61K31/53 , A61K31/501 , A61K31/497 , A61K31/506 , C07D417/12 , C07D417/14
CPC classification number: C07D417/14 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/53 , C07D417/12
Abstract: The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4, and R4 are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
-
公开(公告)号：US09328138B2
公开(公告)日：2016-05-03
申请号：US14358050
申请日：2012-11-09
Applicant: Merck Sharp & Dohme Corp. , MSD Italia S.R.L. , Merck Canada Inc.
Inventor： Michael T. Rudd , John McCauley , Nigel Liverton , Christiane Grisé-Bard , Marie-Christine Brochu , Sylvie Charron , Virender Aulakh , Benoit Bachand , Patrick Beaulieu , Helmi Zaghdane , Yongxin Han , Marco Ferrara , Steven Harper , Vincenzo Summa , Samuel Chackalamannil , Srikanth Venkatraman , Unmesh Shah , Francisco Velazquez
IPC: A61K38/06 , C07K5/08 , C07K5/078 , C07K5/083 , C07K5/087 , A61K38/21 , C07K5/097 , A61K31/4745 , A61K31/5377 , A61K31/675 , A61K31/7056 , A61K38/00 , A61K38/12
CPC classification number: C07K5/08 , A61K31/4745 , A61K31/5377 , A61K31/675 , A61K31/7056 , A61K38/005 , A61K38/06 , A61K38/12 , A61K38/21 , C07K5/0804 , C07K5/0808 , C07K5/0812 , C07K5/0821 , A61K2300/00
Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
-
公开(公告)号：US20150232428A1
公开(公告)日：2015-08-20
申请号：US14422419
申请日：2013-08-15
Applicant: Merck Sharp & Dohme Corp. , Merck Canada Inc.
Inventor： Andrew M. Haidle , Jason Burch , Daniel Guay , Jacques Yves Gauthier , Joel Robichaud , Jean Francois Fournier , John Michael Ellis , Matthew Christopher , Solomon D. Kattar , Graham F. Smith , Alan B. Northrup
IPC: C07D239/42 , C07D239/47 , A61K31/506 , C07D403/12 , A61K31/505 , C07D401/12
CPC classification number: C07D239/42 , A61K31/505 , A61K31/506 , A61K45/06 , C07D239/47 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D471/10
Abstract: The invention provides certain substituted phenyl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
Abstract translation: 本发明提供某些取代的式（I）的苯基化合物或其药学上可接受的盐，其中R1，R2，R3，R4，Rcy和t如本文所定义。 本发明还提供包含这些化合物的药物组合物，以及使用该化合物治疗由脾脏酪氨酸激酶（Syk）介导的疾病或病症的方法。
-
公开(公告)号：US20150148327A1
公开(公告)日：2015-05-28
申请号：US14409151
申请日：2013-06-17
Applicant: Merck Sharp & Dohme Corp. , Merck Canada Inc.
Inventor： Andrew M. Haidle , Sandra Lee Knowles , Solomon D. Kattar , Denis Deschenes , Jason Burch , Joel Robichaud , Matthew Christopher , Michael D. Altman , James P. Jewell , Alan B. Northrup , Marc Blouin , John Michael Ellis , Hua Zhou , Christian Fischer , Adam J. Schell , Michael H. Reutershan , Brandon M. Taoka , Anthony Donofrio , Joel Robichaud
IPC: C07D401/12 , A61K31/506 , C07D471/04 , C07D498/04 , A61K31/5383 , A61K31/551 , C07D405/14 , C07D401/14 , C07D471/10 , C07D491/107 , C07D491/113 , C07D417/14 , C07D413/14 , C07D487/04 , A61K31/5377
CPC classification number: C07D401/12 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/551 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/08 , C07D491/107 , C07D491/113 , C07D498/04 , A61K2300/00
Abstract: The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
Abstract translation: 本发明提供了式（I）的某些取代的吡啶或其药学上可接受的盐，其中R 1，R 2，R 3，R 4，Rcy，Cy和t如本文所定义。 本发明还提供包含这些化合物的药物组合物，以及使用该化合物治疗由脾脏酪氨酸激酶（Syk）激酶介导的疾病或病症的方法。
-
Patent Agency Ranking
公开(公告)号：US09834526B2
公开(公告)日：2017-12-05
申请号：US15104510
申请日：2014-12-17
Applicant: MERCK SHARP & DOHME CORP. , MERCK CANADA INC.
Inventor： John A. McCauley , Christian Beaulieu , David Jonathan Bennett , Christopher J. Bungard , Sheldon Crane , Thomas J. Greshock , Katharine M. Holloway , Daniel McKay , Carmela Molinaro , Oscar Miguel Moradei , Satyanarayana Tummanapalli , Vouy Linh Truong , Peter D. Williams
IPC: A61K31/535 , C07D265/28 , C07D265/30 , A61K45/06 , A61K31/5375 , A61K31/5377 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
CPC classification number: C07D265/30 , A61K31/5375 , A61K31/5377 , A61K45/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04
Abstract: The present invention is directed to 2,5,6-substituted morpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
-
公开(公告)号：US09376418B2
公开(公告)日：2016-06-28
申请号：US14409151
申请日：2013-06-17
Applicant: Merck Sharp & Dohme Corp. , Merck Canada Inc.
Inventor： Andrew M. Haidle , Sandra Lee Knowles , Solomon D. Kattar , Denis Deschenes , Jason Burch , Joel Robichaud , Matthew Christopher , Michael D. Altman , James P. Jewell , Alan B. Northrup , Marc Blouin , John Michael Ellis , Hua Zhou , Christian Fischer , Adam J. Schell , Michael H. Reutershan , Brandon M. Taoka , Anthony Donofrio
IPC: C07D401/12 , C07D401/14 , A61K31/506 , A61K31/505 , A61K45/06 , A61K31/5377 , A61K31/5383 , A61K31/551 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107 , C07D491/113 , C07D498/04 , C07D491/08 , C07D409/14 , C07D487/10
CPC classification number: C07D401/12 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/551 , A61K45/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/08 , C07D491/107 , C07D491/113 , C07D498/04 , A61K2300/00
Abstract: The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
Abstract translation: 本发明提供了式（I）的某些取代的吡啶或其药学上可接受的盐，其中R 1，R 2，R 3，R 4，Rcy，Cy和t如本文所定义。 本发明还提供包含这些化合物的药物组合物，以及使用该化合物治疗由脾脏酪氨酸激酶（Syk）激酶介导的疾病或病症的方法。
-
公开(公告)号：US09242984B2
公开(公告)日：2016-01-26
申请号：US14409133
申请日：2013-06-18
Applicant: Merck Sharp & Dohme Corp. , Merck Canada Inc.
Inventor： Michelle R. Machacek , Michael D. Altman , Eric T. Romeo , Dilrukshi Vitharana , Brandon Cash , Tony Siu , Hua Zhou , Matthew Christopher , Solomon D. Kattar , Andrew M. Haidle , Kaleen Konrad Childers , Matthew L. Maddess , Michael H. Reutershan , Yves Ducharme , David J. Guerin , Kerrie Spencer , Christian Beaulieu , Vouy Linh Truong , Daniel Guay , Alan B. Northrup , Brandon M. Taoka , Jongwon Lim , Christian Fischer , John W. Butcher , Ryan D. Otte , Binyuan Sun , John Michael Ellis
IPC: C07D401/00 , A61K31/00 , C07D471/04 , C07D403/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D403/14 , C07D409/14
CPC classification number: C07D471/04 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14
Abstract: The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
Abstract translation: 本发明提供了式I的新型吡唑衍生物，其是脾脏酪氨酸激酶的有效抑制剂，并且可用于治疗和预防由所述酶介导的疾病，例如哮喘，COPD，类风湿性关节炎和癌症。
-
公开(公告)号：US20140303171A1
公开(公告)日：2014-10-09
申请号：US14353865
申请日：2012-10-26
Applicant: MERCK CANADA INC.
Inventor： Michael John Boyd , Jean-Francois Chiasson , Sheldon Crane , André Giroux
IPC: C07D333/20 , C07D471/04 , C07D487/04 , C07D413/12 , C07D417/12 , C07D417/14 , C07D277/28 , C07D409/12
CPC classification number: C07D333/20 , C07B59/002 , C07D277/28 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04
Abstract: Compounds of Formula I are disclosed: wherein A, R1, R2, R3, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Abstract translation: 公开了式I化合物：其中A，R1，R2，R3，R4A，R4B，R5，R6和R7如本文所定义。 式I所包括的化合物包括作为HIV蛋白酶抑制剂的化合物。 化合物及其药学上可接受的盐可用于预防或治疗HIV感染以及预防，治疗或延迟艾滋病的发病。 化合物及其盐可以用作药物组合物中的成分，任选与其它抗病毒剂，免疫调节剂，抗生素或疫苗组合使用。
-
公开(公告)号：US20130296382A1
公开(公告)日：2013-11-07
申请号：US13934633
申请日：2013-07-03
Applicant: Merck Canada Inc.
Inventor： Jason Burch , Bernard Cote , Natalie Nguyen , Chun Sing Li , Miguel St-Onge , Danny Gauvreau
IPC: C07D401/06 , A61K45/06 , A61K31/4439
CPC classification number: C07D401/06 , A61K31/4439 , A61K45/06
Abstract: Heteroaromatic compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Abstract translation: 式I的杂芳族化合物是HIV逆转录酶抑制剂，其中R1，R2，R3，R4和R5如本文所定义。 式I化合物及其药学上可接受的盐可用于抑制HIV逆转录酶，预防和治疗HIV感染以及预防，延缓发作或进展以及AIDS治疗。 化合物及其盐可以用作药物组合物中的成分，任选与其它抗病毒剂，免疫调节剂，抗生素或疫苗组合使用。
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.031 seconds)
